103 related articles for article (PubMed ID: 15536183)
1. Fas ligand as a tool for immunosuppression and generation of immune tolerance.
Bohana-Kashtan O; Civin CI
Stem Cells; 2004; 22(6):908-24. PubMed ID: 15536183
[TBL] [Abstract][Full Text] [Related]
2. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces.
Guller S; LaChapelle L
Semin Reprod Endocrinol; 1999; 17(1):39-44. PubMed ID: 10406074
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of apoptotic Fas ligand-expressing tumors decreased antitumor responses by enhanced production of immunosuppressive cytokines.
Wada A; Tada Y; Shimozato O; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2005; 25(1A):299-303. PubMed ID: 15816551
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection.
Kawahara T; Yagita H; Kasai S; Sawa M; Kato K; Okumura K; Futagawa S; Mito M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S119-23. PubMed ID: 9792045
[TBL] [Abstract][Full Text] [Related]
5. The role of Fas ligand in immune privilege.
Green DR; Ferguson TA
Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.
Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Yaniv I; Shirwan H; Askenasy N
Stem Cells; 2007 Jun; 25(6):1448-55. PubMed ID: 17363551
[TBL] [Abstract][Full Text] [Related]
7. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
8. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
Kusuhara M; Matsue H
Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
[TBL] [Abstract][Full Text] [Related]
9. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein.
Shen Y; Young B; Lipman ML
Transplantation; 2006 Apr; 81(7):1041-8. PubMed ID: 16612282
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4.FasL inhibits allogeneic responses in vivo.
Dranitzki-Elhalel M; Huang JH; Rachmilewitz J; Pappo O; Parnas M; Schmidt W; Tykocinski ML
Cell Immunol; 2006 Feb; 239(2):129-35. PubMed ID: 16828466
[TBL] [Abstract][Full Text] [Related]
12. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation.
Pearl-Yafe M; Yolcu ES; Yaniv I; Stein J; Shirwan H; Askenasy N
Bioessays; 2006 Feb; 28(2):211-22. PubMed ID: 16435302
[TBL] [Abstract][Full Text] [Related]
13. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals.
Scholz M; Cinatl J
Med Res Rev; 2005 May; 25(3):331-42. PubMed ID: 15599929
[TBL] [Abstract][Full Text] [Related]
14. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
15. Utility of adenovirus-mediated Fas ligand and bcl-2 gene transfer to modulate rat liver allograft survival.
Wang DS; Li Y; Dou KF; Li KZ; Song ZS
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):505-10. PubMed ID: 17085333
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.
Pearl-Yafe M; Yolcu ES; Stein J; Kaplan O; Shirwan H; Yaniv I; Askenasy N
Exp Hematol; 2007 Oct; 35(10):1601-12. PubMed ID: 17889725
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed exogenous IL-4 And IL-10 paradoxically regulate allogenic T-cell and cardiac myocytes apoptosis through FAS/FASL pathway.
Furukawa H; Oshima K; Tung T; Cui G; Laks H; Sen L
Transplantation; 2008 Feb; 85(3):437-46. PubMed ID: 18301335
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of the aryl hydrocarbon receptor in T-lineage cells induces thymus involution independently of the Fas/Fas ligand signaling pathway.
Nagai H; Kubo M; Abe R; Yamamoto M; Nohara K
Int Immunopharmacol; 2006 Feb; 6(2):279-86. PubMed ID: 16399633
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level.
Frängsmyr L; Baranov V; Nagaeva O; Stendahl U; Kjellberg L; Mincheva-Nilsson L
Mol Hum Reprod; 2005 Jan; 11(1):35-41. PubMed ID: 15579659
[TBL] [Abstract][Full Text] [Related]
20. TRANCE counteracts FasL-mediated apoptosis of murine bone marrow-derived dendritic cells.
Chen A; Xu H; Choi Y; Wang B; Zheng G
Cell Immunol; 2004; 231(1-2):40-8. PubMed ID: 15919368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
